Anthea Wirges
Chief Executive Officer & Co-Founder CARTemis
Anthea is the CEO and has co-founded CARTemis Therapeutics together with PD Dr. Uta E. Höpken and Dr. med. Armin Rehm. She studied Molecular Biology and Biochemistry at the Universities of Jena and Lund and obtained a PhD in Biochemistry. For the past 10 years, she has studied CAR T-cells and their therapeutic application as a researcher. Her work has resulted in several publications and patents in adaptive immunotherapy of cancer. Helmholtz Enterprise and the EIC Women Leadership Programme supported her transition to entrepreneurship. She is also among the winners of the first Women TechEU call.
Seminars
Wednesday 10th February 2027
Building a First-in-Class CXCR5-Targeting Cell Therapy to Overcome Relapse Through Dual Tumour & Microenvironment Targeting
9:45 am
- Harnessing CXCR5 as a novel therapeutic target to address antigen escape while targeting tumorigenic cells and the tumour microenvironment
- Demonstrating the scientific rationale for CXCR5-directed therapies, including the elimination of both malignant B-cells and CXCR5-expressing TFH cells that contribute to disease persistence
- Sharing the latest preclinical progress across oncology and autoimmune indications and looking to the future for clinical development
